Adding chemotherapy to immunotherapy for advanced lung cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding a type of chemotherapy called platinum-based chemo to an immunotherapy drug called tislelizumab helps people with advanced non-small cell lung cancer that has spread and has high PD-L1. The trial aims to see if this combination works better than immunotherapy alone in people with larger tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have stage IV non-small cell lung cancer that has not been treated before
- Your tumor tests positive for a high level of a marker called PD-L1 (50% or more)
- Your largest tumor or at least one area of spread is 5 centimeters (about 2 inches) or larger
- You do not have a genetic change that allows targeted therapy, and you can receive both chemotherapy and immunotherapy
- If you have brain metastases, they must not need whole-brain radiation now, or if they did, it must have finished more than 7 days ago
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of tislelizumab (an immunotherapy drug) with chemotherapy for people with a type of lung cancer that has not spread to other organs and cannot be removed with surgery. The goal is to see if this treatment can shrink tumors and help people live longer.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This study tests a new approach: giving an immunotherapy drug (tislelizumab) plus chemotherapy before surgery or radiation for advanced lung cancer that has spread to chest lymph nodes. The goal is to shrink the cancer first, then remove or treat it, to improve chances of long-term control.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.